



Genzyme Corporation  
500 Kendall Street  
Cambridge MA 02446

October 7, 2009

Dear Fabry Community Member,

We are writing to you now as part of our ongoing commitment to keep you aware of important developments in the Fabry disease community. This letter includes information pertaining to the Allston manufacturing facility and an important change for the Fabry community about the projected timing of the return to full supply of Fabrazyme® (agalsidase beta).

**Allston Manufacturing Facility Update:**

Since our last communication, the restart of the Allston Landing manufacturing facility has been completed. All six bioreactors at the Allston plant are fully operational and have reached the point in their production cycles when their anticipated output and the timing of product release can be predicted with more certainty.

**Fabrazyme Supply Management:**

Genzyme announced in a press release dated 23<sup>rd</sup> September that the Fabrazyme supply shortfall will last through the end of the year, when newly manufactured material is expected to become available. As a result, additional product conservation measures are needed to help ensure that the limited remaining Fabrazyme inventory can be made available to as many patients as possible.

The remaining inventory level at the end of September was sufficient to cover 80 percent of forecasted demand through October, the last remaining month of the original dose conservation plan. From October 1 until the end of 2009, this remaining inventory must be spread over three months which corresponds to 30% of forecasted demand.

Individual treatment decisions will need to be made by patients and physicians with the aid of clinical guidelines from stakeholder working groups and regulatory authorities as locally appropriate. Patients with adjusted dose regimens should be closely monitored during this temporary supply constraint.

For more information on the guidelines for Fabrazyme use that have been developed to date, please refer to the following websites:

**EUROPE:**

EMA press release with EU specific recommendations and Q&As :

<http://www.emea.europa.eu/humandocs/Humans/EPAR/fabrazyme/fabrazyme.htm>

**USA:**

2 US-based Fabry patient organizations which have posted recommendations on supply management developed by the Fabrazyme Stakeholders Working Group (US)

[http://www.fabry.org/fsig.nsf/PDFs/PDFs09/\\$File/FSWG\\_Final2.pdf](http://www.fabry.org/fsig.nsf/PDFs/PDFs09/$File/FSWG_Final2.pdf)

and

<http://www.thenfdf.org/page.php?id=404>

**GENZYME:**

Genzyme's website containing the latest supply updates

<http://supplyupdate.genzyme.com/>

**FIN:**

FIN will house the latest info on the FIN website in the coming days at

<http://www.fabryintnetwork.com/>



## Availability of New Fabrazyme Supply

The first shipments of newly produced Fabrazyme are now expected to occur in mid-December. Genzyme expects that it can begin meeting anticipated full patient demand during the first quarter of 2010. However it should be noted that there is always an element of uncertainty in biologics manufacturing. We will continue to closely monitor the situation and will provide updates as appropriate.

We understand that this is difficult news for the Fabry community and we will continue to work diligently to support physicians and patients worldwide during this challenging time.

Sincerely,

A handwritten signature in black ink that reads "Ralph Kern".

Ralph Z. Kern MD, GM Fabry Disease

Genzyme Corporation

*This document contains forward looking statements regarding Genzyme's future business plans and strategies, including its: estimates of when newly produced Fabrazyme will first be available for shipment; expectations of when it will be able to meet global patient demand for Fabrazyme; expectations regarding the period of shortage and dose conservation. These forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those forecasted. These risks and uncertainties include: that production of Fabrazyme does not continue as planned due to any reason, including bacterial or viral contamination, mechanical failures, cell growth at lower than expected levels, fill/finish inefficiencies, and regulatory issues; that Fabrazyme dose conservation guidelines are not adopted as anticipated; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ending June 30, 2009. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this posting. These statements speak only as of the date of this document, and Genzyme undertakes no obligation to update or revise these statements.*